Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907371 | 0.85 | MAPT (0.45) | NPC1RAB9ATSHRHTTLMNA | |
| SCHEMBL2907292 | 0.84 | NPC1 (0.42) | NPC1RAB9ATSHRHTTLMNA | |
| SCHEMBL2906805 | 0.84 | NPC1 (0.46) | NPC1RAB9ATSHRHTTLMNA | |
| SCHEMBL2245184 | 0.84 | NPC1 (0.39) | BRD4NPC1RAB9ATSHRHTT | |
| SCHEMBL2901726 | 0.82 | MAPT (0.46) | BRD4TSHRHTTSMN1; SMN2POLB | |
| SCHEMBL2901736 | 0.81 | L3MBTL1 (0.40) | NPC1RAB9ATSHRHTTLMNA | |
| SCHEMBL2904554 | 0.81 | NPC1 (0.37) | BRD4NPC1RAB9ATSHRHTT | |
| SCHEMBL12356714 | 0.81 | NCF1 (0.42) | BRD4TSHRPOLB | |
| SCHEMBL2904287 | 0.81 | L3MBTL1 (0.48) | BRD4NPC1RAB9ATSHRHTT | |
| SCHEMBL13685486 | 0.80 | BRD4 (0.41) | BRD4HTTLMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262774-B1 | 2-aminoquinolines as 5-HT5A receptor antagonists, their manufacture and pharmaceutical compositions thereof | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | claimed |
| US-7989628-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-20090227628-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| US-7989628-B2 | 2-aminoquinolines | HOFFMANN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090227628-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227628-A1 | 2-AMINOQUINOLINES | HTR5A, HTR1A, HTR1E | BRD4 2290/4885NPC1 1213/4885RAB9A 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.